Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

82. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk 28416587 2017 04 18 2017 04 18 1468-201X 2017 Apr 17 Heart (British Cardiac Society) Heart Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. heartjnl-2016-310897 10.1136/heartjnl-2016-310897 Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect (...) of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk. The SUMMIT (Study to Understand Mortality and MorbidITy) was a multicentre, randomised, double-blind, placebo-controlled, event-driven trial in 16 485 patients with moderate COPD who had or were at high risk of CVD. Here, we assessed the prespecified secondary endpoint of time to first on-treatment composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or transient ischaemic

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

83. Palliative and end-of-life care conversations in COPD: a systematic literature review

Palliative and end-of-life care conversations in COPD: a systematic literature review 28462236 2018 11 13 2312-0541 3 2 2017 Apr ERJ open research ERJ Open Res Palliative and end-of-life care conversations in COPD: a systematic literature review. 00068-2016 10.1183/23120541.00068-2016 Chronic obstructive pulmonary disease (COPD) is a chronic life-limiting disorder characterised by persistent airflow obstruction and progressive breathlessness. Discussions/conversations between patients (...) and clinicians ensure palliative care plans are grounded in patients' preferences. This systematic review aimed to explore what is known about palliative care conversations between clinicians and COPD patients. A comprehensive search of all major healthcare-related databases and websites was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were quality assessed, employing widely used quality-assessment tools, with only papers scoring moderate

ERJ open research2017 Full Text: Link to full Text with Trip Pro

84. Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD

Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD 28680355 2018 11 13 1452-8258 36 2 2017 Apr Journal of medical biochemistry J Med Biochem Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD. 122-126 10.1515/jomb-2017-0011 Serum procalcitonin (PCT) and C-reactive protein (CRP) are markers of systemic inflammation and bacterial infection. We aimed to compare the usefulness (...) of procalcitonin and CRP in patients with community-acquired pneumonia and exacerbations of chronic obstructive pulmonary disease (COPD). A total of 116 consecutive patients were included in the study: 76 with chronic obstructive pulmonary disease in group 1, and 40 with pneumonia in group 2. Median serum CRP level was 44 mg/L in the COPD group and 132 mg/L in the pneumonia group. Median value of serum PCT was found to be 0.07 in the COPD group and 0.14 ng/mL in the pneumonia group. Serum PCT and CRP levels

Journal of medical biochemistry2017 Full Text: Link to full Text with Trip Pro

85. Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with COPD

Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with COPD 28828380 2018 11 13 2312-0541 3 2 2017 Apr ERJ open research ERJ Open Res Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with COPD. 00124-2016 10.1183/23120541.00124-2016 Biomass and functional small airway disease http://ow.ly/gXu730abpKu. Fernandes Lalita L 0000-0003-2383-7172 Dept of Pulmonary Medicine, Goa Medical College, Goa, India. Gulati Nandani N Dept of Pulmonary (...) NHLBI NIH HHS United States Journal Article 2017 04 12 England ERJ Open Res 101671641 2312-0541 Conflict of interest: Disclosures can be found alongside this article at openres.ersjournals.com 2016 11 14 2017 02 19 2017 8 23 6 0 2017 8 23 6 0 2017 8 23 6 1 epublish 28828380 10.1183/23120541.00124-2016 00124-2016 PMC5555765 BMJ Open. 2013 Feb 01;3(2):null 23377993 COPD. 2005 Jun;2(2):277-83 17136954 Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):701-6 8810608 Lancet. 2012 Dec 15;380(9859):2095-128

ERJ open research2017 Full Text: Link to full Text with Trip Pro

86. Umeclidinium (Rolufta) - COPD

Umeclidinium (Rolufta) - COPD 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 26 January 2017 EMA/CHMP/148961/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Rolufta International non-proprietary name (...) with chronic obstructive pulmonary disease (COPD). The legal basis for this application refers to: Article 10(c) of Directive 2001/83/EC – relating to informed consent from a marketing authorisation holder for an authorised medicinal product. The application submitted is composed of administrative information, quality, non-clinical and clinical data with a letter from GlaxoSmithKline Trading Services Limited allowing the cross reference to relevant quality, non-clinical and/or clinical data. Information on paediatric requirements

European Medicines Agency - EPARs2017

87. Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management

Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management ' ? s E G u s Y G ? T W ? Ž l Ž Ð Ž u ? E | s ? Ž ? ? Ž w w s ? G G Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management E ective Date: February 22, 2017 Scope This guideline provides recommendations for the diagnosis and management of adults aged = 19 years with chronic obstructive pulmonary disease (COPD). Key Recommendations • Use spirometry to con$rm air%ow obstruction in all patients suspected (...) of having COPD. [Amended, 2017] • Promote smoking cessation or reduction (even in long-term smokers) to improve symptom control and slow the progression of COPD, among other bene$ts. [2011] • Refer patients with moderate to severe COPD to pulmonary rehabilitation. [2011] • Implement pharmacologic therapy in a stepwise approach and use the lowest step that achieves optimal control based on the patient’s severity of COPD. [New, 2017] • Develop an exacerbation action plan with the patient for pharmacologic

Clinical Practice Guidelines and Protocols in British Columbia2017

88. Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine?

Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? | Clinical Correlations Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? April 12, 2017 By Christopher V. Cosgriff Peer Reviewed The American College of Physicians (ACP) recommends supplemental long-term oxygen therapy (LTOT) in all patients who have severe resting hypoxemia, defined as a PaO 2 ≤55 mmHg or an SpO 2 ≤88%. In patients (...) , and no benefit for all secondary outcomes; the authors noted that the consistency of the null result across all outcomes strengthens their findings. It can thus be concluded from these studies that LTOT provides a mortality benefit in severely hypoxemic patients with COPD, but does not improve mortality in those with mild-to-moderate hypoxemia. These trials do not indicate an optimal target range for supplemental oxygenation. The currently accepted oxygen saturation target of 88%-92% is an attempt to provide

Clinical Correlations2017

89. Cardiopulmonary response during whole-body vibration training in patients with severe COPD

Cardiopulmonary response during whole-body vibration training in patients with severe COPD 28326310 2018 11 13 2312-0541 3 1 2017 Jan ERJ open research ERJ Open Res Cardiopulmonary response during whole-body vibration training in patients with severe COPD. 00101-2016 10.1183/23120541.00101-2016 Several studies in patients with chronic obstructive pulmonary disease (COPD) have shown that whole-body vibration training (WBVT) has beneficial effects on exercise capacity. However, the acute (...) cardiopulmonary demand during WBVT remains unknown and was therefore investigated in this study. Ten patients with severe COPD (forced expiratory volume in 1 s: 38±8% predicted) were examined on two consecutive days. On day one, symptom-limited cardiopulmonary exercise testing was performed on a cycle ergometer. The next day, six bouts of repeated squat exercises were performed in random order for one, two or three minutes either with or without WBVT while metabolic demands were simultaneously measured. Squat

ERJ open research2017 Full Text: Link to full Text with Trip Pro

90. Community pharmacy COPD services: what do researchers and policy makers need to know?

Community pharmacy COPD services: what do researchers and policy makers need to know? 29354551 2018 11 13 2230-5254 6 2017 Integrated pharmacy research & practice Integr Pharm Res Pract Community pharmacy COPD services: what do researchers and policy makers need to know? 53-59 10.2147/IPRP.S105279 COPD is a leading cause of morbidity and mortality across the world and is responsible for a disproportionate use of health care resources. It is a progressive condition that is largely caused (...) by smoking. Identification of early stage COPD provides an opportunity for interventions, such as smoking cessation, which prevent its progression. Once diagnosed, ongoing support services potentially provide an opportunity to assist the patient in managing their condition and working more closely with the rest of the primary care team. While there are a number of robust studies which have demonstrated the role which pharmacists could undertake to identify and prevent disease progression, adoption

Integrated pharmacy research & practice2017 Full Text: Link to full Text with Trip Pro

91. β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial.

β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 28154818 2017 02 03 2017 02 24 3 1 2017 Jan ERJ open research ERJ Open Res β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 00090-2016 10.1183/23120541.00090-2016 A feasibility randomised controlled trial of β-blockers in acute exacerbations of COPD http://ow.ly/lVcy305B36D. Chang Catherina L CL Respiratory Research Unit, Dept of Respiratory Medicine, Waikato Hospital, Hamilton

ERJ open research2017 Full Text: Link to full Text with Trip Pro

92. Management of severe COPD.

Management of severe COPD. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and the burden of the disorder will continue to increase over the next 20 years despite medical intervention. Apart from smoking cessation, no approach or agent affects the rate of decline in lung function and progression of the disease. Especially in the later phase, COPD is a multicomponent disorder, and various integrated intervention strategies are needed as part

Lancet2017

93. Burden and clinical features of chronic obstructive pulmonary disease (COPD).

Burden and clinical features of chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality and represents a substantial economic and social burden throughout the world. It is the fifth leading cause of death worldwide and further increases in its prevalence and mortality are expected in the coming decades. The substantial morbidity associated with COPD is often underestimated by health-care providers (...) and patients; likewise, COPD is frequently underdiagnosed and undertreated. COPD develops earlier in life than is usually believed. Tobacco smoking is by far the major risk for COPD and the prevalence of the disease in different countries is related to rates of smoking and time of introduction of cigarette smoking. Contribution of occupational risk factors is quite small, but may vary depending on a country's level of economic development. Severe deficiency for alpha-1-antitrypsin is rare and the impact

Lancet2017

94. Management of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline

Management of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Jadwiga A. Wedzicha(ERS co-chair) 1 , Marc Miravitlles 2 ,JohnR.Hurst 3 , Peter M.A. Calverley 4 , Richard K. Albert 5 , Antonio Anzueto 6 , GerardJ. Criner 7 , Alberto Papi 8 , Klaus F. Rabe 9 , DavidRigau 10 , Pawel Sliwinski 11 ,ThomyTonia 12 , Jørgen Vestbo 13 , Kevin C. Wilson 14 and JerryA. Krishnan (ATSco (...) , Hospital Universitari Vall d’Hebron, Pg. Vall d’Hebron 119–129, Barcelona 08035, Spain. E-mail: mmiravitlles@vhebron.net @ERSpublications New guideline on the management of #COPD exacerbations from @ERStalk and @atscommunity http://ow.ly/Pvtr307YCMu Cite this article as: /orcid.org/0000-0002-6924-4500Papi A, Rabe KF, Rigau D, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49: 1600791 [https://doi.org/10.1183/13993003.00791

American Thoracic Society2017

95. Prevention of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline

Prevention of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline Prevention of COPD exacerbations: a European Respiratory Society/ American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) 1 , Peter M.A. Calverley 2 , Richard K. Albert 3 , Antonio Anzueto 4 , Gerard J. Criner 5 , John R. Hurst 6 , Marc Miravitlles 7 , Alberto Papi 8 , Klaus F. Rabe 9 , David Rigau 10 , Pawel Sliwinski 11 , Thomy Tonia 12 , Jørgen Vestbo 13 , Kevin C. Wilson 14 and Jerry A. Krishnan (...) , Hospital Universitari Vall d’Hebron, Pg. Vall d’Hebron 119–129, Barcelona 08035, Spain. E-mail: mmiravitlles@vhebron.net @ERSpublications Different strategies are useful for the prevention of COPD exacerbations http://ow.ly/dqpD30daO4O Cite this article as: Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 50: 1602265 [https://doi.org/10.1183/13993003.02265-2016]. ABSTRACT This document

American Thoracic Society2017

99. Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) overlap syndrome

Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) overlap syndrome

DynaMed Plus2017